Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Substudy 06D of an open-label phase I/II umbrella platform trial of sacituzumab tirumotecan combination therapy as second-line treatment for advanced or metastatic gastroesophageal adenocarcinoma
CTR20243025Phase 2Active
- Sponsor
- MSD
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by MSD. Started Sep 2024; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20243025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243025.